MK-2206 Not Superior to Everolimus for Renal Cell Carcinoma

Share this content:
Allosteric inhibition of AKT with MK-2206 is not superior to everolimus for the treatment of patients with advanced renal cell carcinoma.
Allosteric inhibition of AKT with MK-2206 is not superior to everolimus for the treatment of patients with advanced renal cell carcinoma.

Allosteric inhibition of AKT with MK-2206 is not superior to everolimus for the treatment of patients with advanced renal cell carcinoma (RCC) refractory to anti-vascular endothelial growth factor (VEGF) therapy, according to a study published in the Annals of Oncology.1

Upregulation of the phosphoinositide-3 phosphate kinase (PI3K) pathway is associated with worse outcomes for patients with advanced RCC. Researchers hypothesized that inhibiting AKT in patients refractory to anti-VEGF therapy would eliminate key drivers of tumor growth and cancer pathway signaling, prolonging progression-free survival.

Researchers enrolled 43 patients with metastatic or unresectable RCC refractory to anti-VEGF treatment. In this open-label, phase 2 study (ClinicalTrials.gov Identifier: NCT01239342), participants were randomly assigned 2:1 to receive MK-2206, a selective allosteric inhibitor of AKT, or everolimus.

Results of the first futility analysis showed that median progression-free survival was 3.68 months with MK-2206 compared with 5.98 months with everolimus, leading to study closure.

Researchers observed 1 complete response and 3 partial responses in the MK-2206 treatment arm vs no complete or partial responses in the everolimus arm, though progressive disease was the best response in 44.8% of patients treated with MK-2206 and 14.3% of those given everolimus.

RELATED: Survival After Pediatric Cancer: Reducing the Lifetime Burden

Treatment with MK-2206 was associated with a significantly higher incidence of rash and pruritus than everolimus. About 38% of patients in the experimental arm required dose reduction vs 21.4% of everolimus-treated patients.

MK-2206 is being studied in a variety of solid tumors and hematologic malignancies, including in the I-SPY 2 adaptive clinical trial for breast cancer.

Reference

  1. Jonasch E, Hasanov E, Corn P, et al. A randomized phase 2 study of MK-2206 versus everolimus in refractory renal cell carcinoma. Ann Oncol. 2017 Jan 3. doi: 10.1093/annonc/mdw676 [Epub ahead of print]
Loading links....

Related Resources

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs

Sign Up for Free e-newsletters